Debate Continues on Administration of Magnesium Sulfate to Pregnant Women to Prevent Cerebral Palsy in Pre-Term Infants
New York, 29 June 2009 – Cerebral palsy (CP) is the most prevalent chronic childhood motor disability with an estimated lifetime cost of nearly $1 million per individual. There is evidence that magnesium sulfate (MgSO4) can reduce the incidence of CP for very early preterm infants. Many thousands of pregnant women and their fetuses are exposed to MgSO4 every year in the United States for a variety of indications, and most obstetricians are comfortable with its use. Yet, there is still some controversy over whether magnesium sulfate is truly protective against CP. In three articles published in the June 2009 issue of the American Journal of Obstetrics & Gynecology, the authors shed some light on the debate.
Investigators from the Perinatology Research Branch (Division of Intramural Research), Eunice Kennedy Shriver National Institute of Child Health and Human Development, of the NIH, Bethesda, and Detroit, and the Center for Molecular Medicine and Genetics, Wayne State University, Detroit, conducted a systematic review and meta-analysis of six randomized controlled trials involving 4796 women and 5357 infants. Writing in the article, Dr. Roberto Romero and Dr. Agustin Conde-Agudelo concluded that “Antenatal magnesium sulfate should be considered for use in women at high risk of delivery before 34 weeks of gestation, mainly in those with premature rupture of membranes, labor in active phase, and planned delivery within 24 hours.” They found persuasive evidence that administration of magnesium sulfate significantly reduces the risk of cerebral palsy in children at risk.
Continuing the debate, in an article summarizing a roundtable discussion at the 29th Annual Meeting of the Society for Maternal–Fetal Medicine, San Diego, CA, January 30, 2009, two researchers from the Division of Maternal–Fetal Medicine, Department of Obstetrics and Gynecology, Washington University–St. Louis,, and the Division of Maternal–Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California–San Francisco, enumerate the pros and cons of magnesium sulfate use for CP prevention. In a spirited conversation, they each talk about the available trials and observational studies and the strengths and weaknesses of each.
Participating in the roundtable, Alison G. Cahill, MD, MSCI, and Aaron B. Caughey, MD, PhD, observe, “Despite well-designed and executed studies, the answer to the question of whether evidence-based medicine supports the use of magnesium for neuroprophylaxis in all preterm pregnancies remains unclear.”
Dwight J. Rouse, MD, of the Center for Women’s Reproductive Health, University of Alabama at Birmingham, offers his clinical opinion on the use of MgSO4 to prevent cerebral palsy. He notes that “three large, randomized placebo-controlled trials of antenatal magnesium sulfate (MgSO4) for fetal neuroprotection have recently been conducted and reported. The results of these trials provide strong support for the utilization of MgSO4 to lower the risk of cerebral palsy among the survivors of early preterm birth. In the United States, the use of MgSO4 for fetal neuroprotection has the potential to prevent 1000 cases of handicapping cerebral palsy annually.”
The articles are:
“Antenatal Magnesium Sulfate for the Prevention of Cerebral Palsy in Preterm Infants <34 Weeks’ Gestation: A Systematic Review and Meta-Analysis” by Agustín Conde-Agudelo, MD, MPH, and Roberto Romero, MD
“Magnesium for Neuroprophylaxis: Fact or Fiction?” by Alison G. Cahill, MD, MSCI, and Aaron B. Caughey, MD, PhD
“Magnesium Sulfate for the Prevention of Cerebral Palsy” by Dwight J. Rouse, MD
These contributions appear in the American Journal of Obstetrics & Gynecology, Volume 200, Issue 6 (June 2009) published by Elsevier.
# # #
Full text of the article is available upon request. Contact Pamela Poppalardo at 732-238-3628 or email@example.com to obtain a copy or request an interview.
About The American Journal of Obstetrics & Gynecology
The American Journal of Obstetrics & Gynecology, known as “The Gray Journal,” presents coverage of the entire spectrum of the field, from the newest diagnostic procedures to leading-edge research. The Journal provides comprehensive coverage of the specialty, including maternal-fetal medicine, reproductive endocrinology/infertility, and gynecologic oncology. It also publishes the annual meeting papers of several of its 7 sponsoring societies, including the Society for Maternal-Fetal Medicine and the Society of Gynecologic Surgeons.
The American Journal of Obstetrics & Gynecology's 2007 Impact Factor is 2.917 (previously 2.805) and it continues to be ranked #1 in citations in the Obstetrics & Gynecology category, according to the latest Journal Citation Reports® 2008, published by Thomson Reuters. Having moved up to the #7 position, the Journal’s standard of excellence and continued success can be attributed to the strong leadership of the Editors-in-Chief, Thomas J. Garite, MD, and Moon H. Kim, MD, and their outstanding nationally and internationally recognized editorial board and reviewers. The journal has also been recognized as one of the 100 most influential journals in Biology & Medicine over the last 100 years, as determined by the BioMedical & Life Sciences Division of the Special Libraries Association (2009).
Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com